Highlights of This Issue 1399

SPECIAL FEATURES

CCR Translations

1401 Myeloid Suppressors Decrease Melanoma Survival by Abating Tumor-Fighting T Cells
Rolf Kiessling, Yumeng Mao, and Yago Pico de Coa
See related article, p. 1601

Statistics in Clinical Cancer Research

1404 Getting More Out of Survival Data by Using the Hazard Function
Kenneth R. Hess and Victor A. Levin

Molecular Pathways

1410 Molecular Pathways: HER3 Targeted Therapy
Kinisha Gala and Sarat Chandarlapaty

CCR Focus

1418 It’s All About the Test: The Complexity of Companion Diagnostic Co-development in Personalized Medicine
Susan E. Bates

1419 Developing Precision Medicine in a Global World
Eric H. Rubin, Jeffrey D. Allen, Jan A. Nowak, and Susan E. Bates

1428 Evidence of Clinical Utility: An Unmet Need in Molecular Diagnostics for Patients with Cancer

1445 Similarities and Differences in the Oncology Drug Approval Process between FDA and European Union with Emphasis on In Vitro Companion Diagnostics
Adrian M. Senderowicz and Otnar Pfaff

1453 FDA Perspective on Companion Diagnostics: An Evolving Paradigm
Elizabeth A. Mansfield

Francesco Pignatti, Falk Ehmann, Robert Hemrnings, Bertil Jonsson, Micha Nuebling, Marisa Papalucua-Amati, Martin Posch, and Guido Rasi

1469 The Health Technology Assessment of Companion Diagnostics: Experience of NICE
Sarah K. Byron, Nick Crabh, Elisabeth George, Mirella Marlow, and Adrian Newland

HUMAN CANCER BIOLOGY

1477 FOXM1c Promotes Pancreatic Cancer Epithelial-to-Mesenchymal Transition and Metastasis via Upregulation of Expression of the Urokinase Plasminogen Activator System
Chen Huang, Dachen Xie, Jiujei Cui, Qi Li, Yong Gao, and Keping Xie

1489 DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression
Mei-Yi Hsieh, Jia-Rong Fan, Han-Wen Chang, Hsiang-Chin Chen, Tang-Long Shen, Shu-Chun Teng, Yen-Hsiu Yeh, and Tsai-Kun Li

1502 hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutic Implications
Olivia Croci, Elena Lastraoli, Luca Boni, Serena Pillozzi, Maria Raffaella Romoli, Massimo D’Amico, Matteo Stefanini, Silvia Crescioli, Antonio Taddei, Lapo Bencini, Marco Bernini, Marco Farsi, Stefania Beghelli, Aldo Scarpa, Luca Messerini, Anna Tommezzoli, Carla Vindigni, Paolo Morgagni, Luca Saragoni, Elisa Giommoni, Silvia Gasperoni, Francesco Di Costanzo, Franco Rovigli, Giovanni De Manzoni, Paolo Bechi, and Annarosa Arcangeli

1513 Calcium/Calmodulin-Dependent Protein Kinase II and Its Endogenous Inhibitor α in Medullary Thyroid Cancer
Eleonora Russo, Marcella Salzano, Valentina De Falco, Caterina Mian, Susi Barollo, Agnese Secondo, Maurizio Bifulco, and Mario Vitale
Phase I Study of Oral Rigosertib (ON 01910. Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies
Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler, Priti Hegde, Shuang Bai, Surinder Kaur, Ihshn Nijem, Daniel V.T. Catenacci, Amy Peterson, Mark J. Ratain, Blase Polite, Janice M. Mehnert, and Rebecca A. Moss

Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome
Abdulmohsen Alhejaily, Andrew G. Day, Harriet E. Feilotter, Tara Baetz, and David P. LeBrun

A Functional Germline Variant in GLI1 Implicates Hedgehog Signaling in Clinical Outcome of Stage II and III Colon Carcinoma Patients

Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Correction: Carbonic Anhydrase IX Promotes Tumor Growth and Necrosis In Vivo and Inhibition Enhances Anti-VEGF Therapy

The cover shows a section of an intracranial glioblastoma (GBM). GBM cells express the fluorescent protein citrine (green) and the High-mobility group protein B1 (HMGB1) fused to the red fluorescent protein cherry. In living cells HMGB1 is located in the nucleus; upon cell death, HMGB1 is translocated to the cytoplasm and is eventually secreted. Circulating levels of HMGB1 may constitute a noninvasive surrogate biomarker of therapeutic efficacy. For details, see the article by Candolfi and colleagues on page 1555 of this issue.

Table of Contents